Leonard M. Lipman, M.D.; Donald E. Green, M.D.; Norton J. Snyder, M.D.; Jerald C. Nelson, M.D.; David H. Solomon, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Long-acting thyroid stimulator (LATS) determinations have been performed on sera of 440 subjects, in order to analyze its relationship to the major clinical features of Graves' disease (hyperthyroidism, ophthalmopathy, and dermopathy). The prevalence of LATS proved to be primarily related to the number of features present and not to any individual feature. The prevalence was lowest (47%) in patients with only one active feature, regardless of which this was, intermediate (63%) in patients with two active features, and highest (89%) in patients with three active features. The previously noted apparently specific relationship of LATS to ophthalmopathy proved fortuitous, being entirely
Lipman LM, Green DE, Snyder NJ, Nelson JC, Solomon DH. Relationship of the Long-acting Thyroid Stimulator (LATS) to the Clinical Features and Course of Graves' Disease.. Ann Intern Med. ;66:1028. doi: 10.7326/0003-4819-66-5-1028_2
Download citation file:
Published: Ann Intern Med. 1967;66(5):1028.
Endocrine and Metabolism, Thyroid Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use